long intergenic non-protein coding RNA 1566Genealiases: []
Q-omics provides the consensus-scored LINC01566 profile across patient tissues and cancer cell-line models. LINC01566 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01566 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, LINC01566 RNA expression shows 5,882 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, PRAD, and STAD as cancer lineages where LINC01566 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01566 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01566 survival associations across molecular data types. LINC01566 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01566 RNA expression–survival associations across cancer types. High LINC01566 expression shows unfavorable associations in ACC, KICH, UCS and BLCA, but favorable associations in SKCM and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01566 RNA expression.
This table summarizes LINC01566 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01566. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01566 shows higher tumor expression in PRAD. The PRAD box plot shows higher LINC01566 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .027).
This table shows molecular features associated with LINC01566 in patient tissues and cancer cell lines. In patient samples, LINC01566 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
